• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    12/9/24 5:37:15 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CDTX alert in real time by email
    SC 13G 1 ea0224118-13gvivo_cidara.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No.      )*

     

    Cidara Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

     

    171757206

    (CUSIP Number)

     

    November 26, 2024

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    1.

    NAMES OF REPORTING PERSONS

     

    Vivo Opportunity Fund Holdings, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☐

    (b) þ

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    600,157 (1)

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    600,157 (1)

    8.

    SHARED DISPOSITIVE POWER

     

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    600,157 (1)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES      ☐

     

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    5.5% (2)

    12.

    TYPE OF REPORTING PERSON

     

    PN

     

    (1)The number represents shares of common stock, $0.0001 par value (the “Common Stock”) of Cidara Therapeutics, Inc. (the “Issuer”) held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

     

    (2)Based on 10,938,907 shares of Common Stock, which is the sum of (i) 7,046,633 shares of Common Stock outstanding as of November 4, 2024, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the Securities and Exchange Commission (the “SEC”) on November 7, 2024, plus (ii) 3,892,274 shares of Common Stock issued at the closing of a private placement offering, as reported by the Issuer in its Current Report on Form 8-K filed with the SEC on November 26, 2024.

     

    2

     

    1.

    NAMES OF REPORTING PERSONS

     

    Vivo Opportunity, LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☐

    (b) þ

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    600,157 (1)

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    600,157 (1)

    8.

    SHARED DISPOSITIVE POWER

     

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    600,157 (1)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES      ☐

     

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    5.5% (2)

    12.

    TYPE OF REPORTING PERSON

     

    OO

     

    (1)The number represents shares of Common Stock of the Issuer held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

     

    (2)Based on 10,938,907 shares of Common Stock, which is the sum of (i) 7,046,633 shares of Common Stock outstanding as of November 4, 2024, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 7, 2024, plus (ii) 3,892,274 shares of Common Stock issued at the closing of a private placement offering, as reported by the Issuer in its Current Report on Form 8-K filed with the SEC on November 26, 2024.

     

    3

     

    1

    NAMES OF REPORTING PERSONS

     

    Vivo Asia Opportunity Fund Holdings, L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☐

    (b) þ

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

     

    5

    SOLE VOTING POWER

     

    70,443 (1)

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    70,443 (1)

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    70,443 (1)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES      ☐

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.6% (2)

    12

    TYPE OF REPORTING PERSON

     

    PN

     

    (1)The number represents shares of Common Stock of the Issuer held of record by Vivo Asia Opportunity Fund Holdings, L.P.  Vivo Opportunity Cayman, LLC is the general partner of Vivo Asia Opportunity Fund Holdings, L.P.

     

    (2)Based on 10,938,907 shares of Common Stock, which is the sum of (i) 7,046,633 shares of Common Stock outstanding as of November 4, 2024, 3 as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 7, 2024, plus (ii) 3,892,274 shares of Common Stock issued at the closing of a private placement offering, as reported by the Issuer in its Current Report on Form 8-K filed with the SEC on November 26, 2024.

     

    4

     

    1

    NAMES OF REPORTING PERSONS

     

    Vivo Opportunity Cayman, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a) ☐

    (b) þ

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

     

    5

    SOLE VOTING POWER

     

    70,443 (1)

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    70,443 (1)

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    70,443 (1)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES      ☐

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    0.6% (2)

    12

    TYPE OF REPORTING PERSON

     

    OO

     

    (1)The number represents shares of Common Stock of the Issuer held of record by Vivo Asia Opportunity Fund Holdings, L.P.  Vivo Opportunity Cayman, LLC is the general partner of Vivo Asia Opportunity Fund Holdings, L.P.

     

    (2)Based on 10,938,907 shares of Common Stock, which is the sum of (i) 7,046,633 shares of Common Stock outstanding as of November 4, 2024, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 7, 2024, plus (ii) 3,892,274 shares of Common Stock issued at the closing of a private placement offering, as reported by the Issuer in its Current Report on Form 8-K filed with the SEC on November 26, 2024.

     

    5

     

    Item 1. (a) Name of Issuer:

     

    Cidara Therapeutics, Inc. (the “Issuer”)

     

      (b) Address of Issuer’s Principal Executive Offices:

     

    6310 Nancy Ridge Drive, Suite 101

    San Diego, CA 92121

     

    Item 2. (a) Name of Person Filing:

     

    Vivo Opportunity Fund Holdings, L.P. and its General Partner Vivo Opportunity, LLC

     

    Vivo Asia Opportunity Fund Holdings, L.P and its General Partner Vivo Opportunity Cayman, LLC

     

      (b) Address of Principal Business Office or, if None, Residence:

     

    192 Lytton Avenue, Palo Alto, CA 94301

     

      (c) Citizenship:

     

    Vivo Opportunity Fund Holdings, L.P. is a Delaware limited partnership.

     

    Vivo Opportunity, LLC is a Delaware limited liability company.

     

    Vivo Asia Opportunity Fund Holdings, L.P. is a Cayman Islands limited partnership.

     

    Vivo Opportunity Cayman, LLC is a Cayman Islands limited liability company.

     

      (d) Title of Class of Securities:

     

    Common Stock, $0.0001 par value

     

      (e) CUSIP Number:

     

    171757206

     

    Item 3. If This Statement is Filed Pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

     

      (a) ☐ Broker or dealer registered under Section 15 of the Act.
           
      (b) ☐ Bank as defined in Section 3(a)(6) of the Act.
           
      (c) ☐  Insurance company as defined in Section 3(a)(19) of the Act.
           
      (d) ☐  Investment company registered under Section 8 of the Investment Company Act of 1940.
           
      (e) ☐  An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) ☐  An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) ☐  A parent holding company or control person in accordance with § 240.13d-1(b)(l)(ii)(G);

    6

     

      (h) ☐  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
           
      (i) ☐  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
           
      (j) ☐  A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
           
      (k) ☐  Group, in accordance with § 240.13d-1(b)(l)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1(ii)(j), please specify the type of institution: ________________

     

    Not Applicable.

     

    Item 4. Ownership.

     

      (a) Amount Beneficially Owned:

     

    Vivo Opportunity, LLC beneficially owns 600,157 shares of Common Stock. The securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.

     

    Vivo Opportunity Cayman, LLC beneficially owns 70,443 shares of Common Stock. The securities are held of record by Vivo Asia Opportunity Fund Holdings, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Asia Opportunity Fund Holdings, L.P.

     

      (b) Percent of class:

     

    Vivo Opportunity Fund Holdings, L.P.: 5.5%

    Vivo Opportunity, LLC: 5.5%

    Vivo Asia Opportunity Fund Holdings, L.P.: 0.6%

    Vivo Opportunity Cayman, LLC.: 0.6%

     

      (c) Number of shares as to which such person has:

     

      (i)

    Sole power to vote or to direct the vote:  

    Vivo Opportunity Fund Holdings, L.P.: 600,157 shares

    Vivo Opportunity, LLC: 600,157 shares

    Vivo Asia Opportunity Fund Holdings, L.P.: 70,443 shares

    Vivo Opportunity Cayman, LLC: 70,443 shares

     

      (ii) Shared power to vote or to direct the vote: 0

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    Vivo Opportunity Fund Holdings, L.P.: 600,157 shares

    Vivo Opportunity, LLC: 600,157 shares

    Vivo Asia Opportunity Fund Holdings, L.P.: 70,443 shares

    Vivo Opportunity Cayman, LLC: 70,443 shares        

     

      (iv) Shared power to dispose of or to direct the disposition of: 0

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    Not applicable.

     

    7

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a11.

     

    8

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: December 9, 2024

     

    Vivo Opportunity Fund Holdings, L.P.

     

    By: Vivo Opportunity, LLC, its General Partner

     

    /s/ Kevin Dai  
    Name: Kevin Dai  
    Title:   Managing Member  

     

    Vivo Opportunity, LLC

     

    /s/ Kevin Dai  
    Name: Kevin Dai  

    Title:   Managing Member

     

     

    Vivo Asia Opportunity Fund Holdings, L.P.

     

    By: Vivo Opportunity Cayman, LLC, its General Partner

     

    /s/ Kevin Dai  
    Name: Kevin Dai  
    Title:   Managing Member  

     

    Vivo Opportunity Cayman, LLC

     

    /s/ Kevin Dai  
    Name: Kevin Dai  
    Title:   Managing Member  

     

    9

     

    EXHIBIT INDEX

     

    Exhibit    
         
    99.1   Joint Filing Statement

     

    10

     

    Get the next $CDTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDTX

    DatePrice TargetRatingAnalyst
    3/12/2025$46.00Mkt Outperform
    Citizens JMP
    1/27/2025Overweight
    Cantor Fitzgerald
    12/13/2024$34.00Outperform
    RBC Capital Mkts
    11/8/2024$33.00Buy
    Guggenheim
    8/14/2024$24.00Neutral → Buy
    H.C. Wainwright
    12/3/2021$6.00Buy
    H.C. Wainwright
    9/22/2021$9.00 → $8.00Buy
    Aegis Capital
    9/22/2021$6.25Buy → Strong Buy
    WBB Securities
    More analyst ratings

    $CDTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025

      SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that it will host a virtual research and development (R&D) day on Thursday, May 22, 2025, from 10:00 to 11:30 AM ET. To register, click here. The event will feature key opinion leaders (KOLs) Fred Hayden, MD, FACP (University of Virginia School of Medicine) and Rick Bright, PhD (Pandemic Prevention Institute, The Rockefeller Foundation), who will join company management to discuss CD388, Cidara's long-acting antiviral drug designed to revolutionize influenza pro

      5/15/25 8:00:00 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

      SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below investor conferences. Event: RBC Global Healthcare ConferenceDate: Wednesday, May 21, 2025Time: 10:00 AM ET Event: Jefferies Global Healthcare ConferenceDate: Wednesday, June 4, 2025Time: 11:40 AM ET The live webcast for the presentations can be accessed in the Investors section on the Company's website at https://www.cidara.com/investors/events/. Replays of the presentations will be available for at least 30 days. Cida

      5/13/25 8:00:00 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

      Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025Nature Microbiology publication highlights preclinical data and the potential of CD388 as a potent, universal antiviral for influenza prevention in healthy and high-risk populations regardless of immune statusConference call and webcast today at 5:00 PM Eastern Time SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today reported financial results for the first quarter ended March 31, 2025, and pro

      5/8/25 4:15:38 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CDTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Stein Jeffrey bought $105,680 worth of shares (8,000 units at $13.21) (SEC Form 4)

      4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

      6/11/24 6:26:28 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CDTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Cidara Therapeutics Inc.

      SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

      12/9/24 5:37:15 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Cidara Therapeutics Inc.

      SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

      12/4/24 4:15:14 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Cidara Therapeutics Inc.

      SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

      12/3/24 4:34:49 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CDTX
    Leadership Updates

    Live Leadership Updates

    See more

    $CDTX
    SEC Filings

    See more

    $CDTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

      FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors. Mr. Schroeder brings more than three decades of experience leading innovative biopharmaceutical companies and has a strong track record of building and scaling commercial organizations, bringing new therapies to market, and successfully guiding companies through key business milestones and strategic transactions. "We are pleased to welcome Ted to the Phathom Board during a pivotal period for the com

      4/16/25 8:00:46 AM ET
      $CDTX
      $PHAT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      Completed enrollment of 5,000 subject Phase 2b NAVIGATE trialSevere flu season enables potential mid-year assessment of efficacyClosed $105.0 million financing with new and existing investorsSignificantly expanded equity research coverage SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided recent business updates. "2024 was a transformational year for Cidara as we reacquired rights to the CD388 program

      3/6/25 4:35:37 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer

      SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Frank Karbe, MBA, has been appointed Chief Financial Officer (CFO), effective February 24, 2025. Mr. Karbe will succeed Preetam Shah, Ph.D., MBA, who is departing to pursue other professional opportunities. Dr. Shah will serve as a consultant to the Company. "We are pleased to welcome Frank to the team as we advance our long-acting influenza antiviral drug CD388 through the e

      2/18/25 4:15:00 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Cidara Therapeutics Inc.

      EFFECT - Cidara Therapeutics, Inc. (0001610618) (Filer)

      5/16/25 12:15:29 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Cidara Therapeutics Inc.

      SCHEDULE 13G/A - Cidara Therapeutics, Inc. (0001610618) (Subject)

      5/15/25 4:25:28 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Cidara Therapeutics Inc.

      SCHEDULE 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

      5/12/25 9:04:22 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Davarpanah Nicole Negar was granted 10,000 shares, increasing direct ownership by 46% to 31,692 units (SEC Form 4)

      4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

      5/12/25 8:40:21 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Davarpanah Nicole Negar claimed ownership of 21,692 shares (SEC Form 3)

      3 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

      5/12/25 8:37:41 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by President & CEO Stein Jeffrey

      4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)

      4/2/25 6:28:15 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CDTX
    Financials

    Live finance-specific insights

    See more
    • Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

      Data cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data readout expected in late June 2025Nature Microbiology publication highlights preclinical data and the potential of CD388 as a potent, universal antiviral for influenza prevention in healthy and high-risk populations regardless of immune statusConference call and webcast today at 5:00 PM Eastern Time SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today reported financial results for the first quarter ended March 31, 2025, and pro

      5/8/25 4:15:38 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025

      SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its first quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, May 8, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast Information Date:Thursday, May 8, 2025Time:5:00 PM Eastern TimeUnited States:1-800-717-1738International:1-646-307-1865Conferen

      4/24/25 8:00:00 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million

      - $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinical trial - CD388, which is active against all strains of influenza A and B, is being developed for pre-exposure prophylactic treatment - Company to host business strategy update conference call and webcast today at 4:30 PM ET SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve

      4/24/24 4:05:00 PM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CDTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citizens JMP initiated coverage on Cidara Therapeutics with a new price target

      Citizens JMP initiated coverage of Cidara Therapeutics with a rating of Mkt Outperform and set a new price target of $46.00

      3/12/25 7:22:04 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cantor Fitzgerald resumed coverage on Cidara Therapeutics

      Cantor Fitzgerald resumed coverage of Cidara Therapeutics with a rating of Overweight

      1/27/25 8:36:28 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • RBC Capital Mkts initiated coverage on Cidara Therapeutics with a new price target

      RBC Capital Mkts initiated coverage of Cidara Therapeutics with a rating of Outperform and set a new price target of $34.00

      12/13/24 7:27:23 AM ET
      $CDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care